Nevertheless, only a fraction of patients responds to monotherapy; the combination of CTLA-4 and PD-1 blockers showed a remarkable increase in response rates and median survival time in melanoma and renal cell carcinoma [52,53,54]. The gene discussed is PDCD1; the disease is renal cell carcinoma.